Abbott completes separation of research-based pharmaceuticals business

08-Jan-2013 - USA

Abbott  announced it has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie begins trading independently on the New York Stock Exchange under the symbol "ABBV."

"We wish our colleagues at AbbVie continued success as they become part of a new, independent company that is already making a significant difference, focusing on highly specialized, market-leading therapies for some of the world's most difficult-to-treat diseases," said Miles D. White, chairman and chief executive officer, Abbott.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...